You have full text access to this OnlineOpen article

Innovations in understanding the biology of cervical cancer

  1. Judith K. Wolf M.D.1,*,
  2. Eduardo L. Franco Ph.D., M.P.H.2,3,
  3. Jeffery M. Arbeit M.D.4,
  4. Kenneth R. Shroyer M.D., Ph.D.5,
  5. Tzyy-Choou Wu M.D., Ph.D.6,7,8,9,
  6. Carolyn D. Runowicz M.D.10,
  7. Guillermo Tortolero-Luna M.D., Ph.D.1,
  8. Rolando Herrero M.D.11,
  9. Christopher P. Crum M.D.12

Article first published online: 22 OCT 2003

DOI: 10.1002/cncr.11682

Issue

Cancer

Cancer

Special Issue: Proceedings of the Second International Conference on Cervical Cancer

Supplement: Second International Conference on Cervical Cancer

Volume 98, Issue Supplement S9, pages 2064–2069, 1 November 2003

Additional Information

How to Cite

Wolf, J. K., Franco, E. L., Arbeit, J. M., Shroyer, K. R., Wu, T.-C., Runowicz, C. D., Tortolero-Luna, G., Herrero, R. and Crum, C. P. (2003), Innovations in understanding the biology of cervical cancer. Cancer, 98: 2064–2069. doi: 10.1002/cncr.11682

Author Information

  1. 1

    Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Epidemiology and Biostatistics, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

  3. 3

    Department of Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

  4. 4

    Cancer Genetics Program, Comprehensive Cancer Center, University of California–San Francisco, San Francisco, California

  5. 5

    Department of Pathology, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado

  6. 6

    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland

  7. 7

    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland

  8. 8

    Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, Maryland

  9. 9

    Department of Molecular Microbiology and Immunology, The Johns Hopkins Medical Institutions, Baltimore, Maryland

  10. 10

    St. Luke's–Roosevelt Hospital Center, Women's Health Service Line of Continuum Heath Partners, Inc., New York, New York

  11. 11

    Proyecto Epidemiologico Guanacaste, Santa Ana, Costa Rica

  12. 12

    Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

*Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 440, Houston, TX 77030

Publication History

  1. Issue published online: 22 OCT 2003
  2. Article first published online: 22 OCT 2003
  3. Manuscript Accepted: 13 FEB 2003
  4. Manuscript Revised: 7 FEB 2003
  5. Manuscript Received: 31 OCT 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (85K)

REFERENCES

  • 1
    Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983; 80: 3812–3815.
  • 2
    Kremsdorf D, Jablonska S, Favre M, Orth G. Biochemical characterization of two types of human papillomaviruses associated with epidermodysplasia verruciformis. J Virol. 1982; 43: 436–447.
  • 3
    Crum CP, Ikenberg H, Richart RM, Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med. 1984; 310: 880–883.
  • 4
    Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645–1651.
  • 5
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338: 423–428.
  • 6
    Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999; 180: 1415–1423.
  • 7
    Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001; 183: 8–15.
  • 8
    Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001; 286: 3106–3114.
  • 9
    Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000; 92: 464–474.
  • 10
    Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica. 1999; 6: 223–233.
  • 11
    Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis. 2000; 27: 79–86.
  • 12
    Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997; 1: 362–375.
  • 13
    Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000; 283: 87–93.
  • 14
    Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000; 9: 945–951.
  • 15
    Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83: 439–444.
  • 16
    Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001; 84: 1219–1226.
  • 17
    Jarboe EA, Liaw KL, Thompson LC, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene. 2002; 21: 664–673.
  • 18
    Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000; 60: 1267–1275.
  • 19
    Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res. 1999; 59: 3991–3997.
  • 20
    Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A. 1996; 93: 2930–2935.
  • 21
    Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol. 2001; 8: 83–92.
  • 22
    Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol. 2001; 32: 479–486.
  • 23
    Cviko A, Briem B, Granter SR, et al. Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates. Hum Pathol. 2000; 31: 740–744.
  • 24
    Frost M, Bobak JB, Gianani R, et al. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am J Clin Pathol. 2000; 114: 726–734.
  • 25
    Shroyer KR, Thompson LC, Enomoto T, Eskens JL, Shroyer AL, McGregor JA. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix. Am J Clin Pathol. 1998; 109: 153–162.
  • 26
    Chen C, Wang T, Hung C, Pardoll DM, Wu T. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 2000; 18: 2015–2022.
  • 27
    Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol. 2001; 75: 9654–9664.
  • 28
    Cheng WF, Hung CF, Hsu KF, et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther. 2001; 12: 235–252.
  • 29
    Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. 1999; 6: 1972–1981.
  • 30
    Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999; 10: 2727–2740.
  • 31
    Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001; 108: 669–678.
  • 32
    Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility Class II presentation of tumor antigen. Cancer Res. 1996; 56: 21–26.
  • 33
    Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002; 347: 1703–1705.
View Full Article (HTML) Get PDF (85K)